Alchem Laboratories and Applied Pharmaceutical Innovation Forge Strategic Alliance to Advance Antimicrobial Programs (Newswires)
UF Innovate | Accelerate client company Alchem Laboratories and Applied Pharmaceutical Innovation announced the formation of a strategic alliance to explore and advance joint initiatives in the fields of antimicrobials and essential medicine therapeutics, improving supply chain resiliency.
NovaBone To Unveil First-of-Its-Kind Bioactive Wedge at AOFAS 2025 Annual Meeting in Savannah (PR Newswire)
UF startup NovaBone, a pioneer in synthetic bone graft technologies, will showcase its Bioactive Pre-contoured Wedge (BPW) at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting.
UF Researchers ‘Rewriting Organ Biology’ With Revolutionary Transplant Technology (UF HWCE)
UF Innovate | Accelerate client company CasNx is pioneering CRISPR-based technology to cleanse and enhance donor organs before transplant, reducing viral risks and improving patient outcomes.
New Lightning Sensors Could Detect Tahoe Wildfires in Seconds. Here’s How They Work
A real-time lightning detection system developed by UF Innovate | Accelerate resident client FNN is helping California officials better prepare for wildfires, offering earlier alerts to reduce disaster risk.
Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial
UF Innovate | Accelerate graduate Oragenics, Inc., announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the Company’s novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Taming Wild Fires Before They Spiral: Part 2 – User Experience
UF Innovate | Accelerate resident client Fire Neural Network (FNN) was spotlighted for its AI-powered wildfire detection system, which emphasizes user experience in addressing critical environmental challenges.
SandboxAQ and iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery for Glioblastoma
SandboxAQ and UF startup iOncologi have announced a strategic collaboration to co-develop, validate, and commercialize a novel high-fidelity mRNA vaccine targeting glioblastoma—the most common and aggressive malignant brain tumor in adults.
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development
UF Innovate | Accelerate graduate Oragenics, Inc., has announced a manufacturing agreement with Sterling Pharma Solutions, a leading U.S.-based CDMO with multiple development and production facilities.
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences, which acquired UF startup AavantiBio, announced FDA and Health Canada approval to begin clinical trials of SGT-501, a gene therapy targeting CPVT, a severe heart rhythm disorder caused by RYR2 mutations.